Neuroacanthocytosis

Neuroacanthocytosis (NA) is a group of rare neurodegenerative disorders characterized by the presence of acanthocytes (spiky, misshapen red blood cells) in the peripheral blood along with progressive neurological symptoms. The Orphanet code 263440 refers to the broader neuroacanthocytosis syndrome group, which encompasses several distinct conditions including chorea-acanthocytosis (ChAc), McLeod syndrome, Huntington disease-like 2 (HDL2), and pantothenate kinase-associated neurodegeneration (PKAN). These disorders primarily affect the central nervous system, particularly the basal ganglia, as well as the peripheral nervous system and red blood cells. The hallmark clinical features of neuroacanthocytosis syndromes include progressive movement disorders such as chorea (involuntary jerky movements), dystonia, parkinsonism, and tics. Patients frequently develop orofacial dyskinesias, including tongue and lip biting, which can lead to self-mutilation. Seizures are common, particularly in chorea-acanthocytosis. Psychiatric manifestations including personality changes, obsessive-compulsive behaviors, depression, and cognitive decline are frequently observed. Peripheral neuropathy and muscle wasting (amyotrophy) may also occur. Elevated serum creatine kinase levels and hepatosplenomegaly can be present depending on the specific subtype. There is currently no cure or disease-modifying treatment for neuroacanthocytosis syndromes. Management is symptomatic and supportive. Movement disorders may be partially managed with medications such as antipsychotics or tetrabenazine, though response is often limited. Seizures are treated with antiepileptic drugs. Botulinum toxin injections may help with dystonia. Deep brain stimulation has been explored in some cases with variable results. A multidisciplinary approach involving neurologists, psychiatrists, speech therapists, and other specialists is essential for optimizing quality of life.

Common questions about Neuroacanthocytosis